P. Huang, Phosphoproteomic studies of receptor tyrosine kinases: future perspectives, Mol. BioSyst., vol.27, issue.4, pp.1100-1107, 2012.
DOI : 10.1038/nbt.1513

S. Hubbard and W. Miller, Receptor tyrosine kinases: mechanisms of activation and signaling, Current Opinion in Cell Biology, vol.19, issue.2, pp.117-140, 2007.
DOI : 10.1016/j.ceb.2007.02.010

M. Lemmon and J. Schlessinger, Cell Signaling by Receptor Tyrosine Kinases, Cell, vol.141, issue.7, pp.1117-1151, 2010.
DOI : 10.1016/j.cell.2010.06.011

T. Regad, Targeting RTK Signaling Pathways in Cancer, Cancers, vol.62, issue.4, pp.1758-84, 2015.
DOI : 10.1007/s00018-013-1324-2

C. Abou-fayçal, A. Hatat, S. Gazzeri, and B. Eymin, Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy, International Journal of Molecular Sciences, vol.23, issue.12
DOI : 10.1038/nm.4097

N. Iqbal and N. Iqbal, Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications, Molecular Biology International, vol.30, issue.649, p.852748, 2014.
DOI : 10.1007/s10549-012-2003-y

K. Hatanpaa, S. Burma, D. Zhao, and A. Habib, Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance, Neoplasia, vol.12, issue.9, pp.675-84, 2010.
DOI : 10.1593/neo.10688

B. Voldborg, L. Damstrup, M. Spang-thomsen, and H. Poulsen, Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials, Annals of Oncology, vol.8, issue.12, pp.1197-206, 1997.
DOI : 10.1023/A:1008209720526

J. Mckay, L. Murray, S. Curran, V. Ross, C. Clark et al., Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases, European Journal of Cancer, vol.38, issue.17, pp.2258-64, 2002.
DOI : 10.1016/S0959-8049(02)00234-4

A. Gazdar, Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors, Oncogene, vol.19, issue.S1, pp.24-31, 2009.
DOI : 10.1016/j.cell.2006.05.013

P. Liu, W. Gan, Y. Chin, K. Ogura, J. Guo et al., PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex, Cancer Discovery, vol.5, issue.11, pp.1194-209, 2015.
DOI : 10.1158/2159-8290.CD-15-0460

L. Santarpia, S. Lippman, and A. El-naggar, Targeting the MAPK???RAS???RAF signaling pathway in cancer therapy, Expert Opinion on Therapeutic Targets, vol.24, issue.15, pp.103-122, 2012.
DOI : 10.1056/NEJMoa1014209

J. Mccubrey, L. Steelman, W. Chappell, S. Abrams, E. Wong et al., Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1773, issue.8, pp.1263-84, 2007.
DOI : 10.1016/j.bbamcr.2006.10.001

D. Fruman and C. Rommel, PI3K and cancer: lessons, challenges and opportunities, Nature Reviews Drug Discovery, vol.286, issue.2, pp.140-56, 2014.
DOI : 10.1126/science.286.5445.1741
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994981/pdf

F. Chang, J. Lee, P. Navolanic, L. Steelman, J. Shelton et al., Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis and neoplastic transformation: a target for cancer chemotherapy, Leukemia, vol.142, issue.Suppl, pp.590-603, 2003.
DOI : 10.1210/endo.142.11.8467

J. Blenis and . Tor, TOR, the Gateway to Cellular Metabolism, Cell Growth, and Disease, Cell, vol.171, issue.1, pp.10-13, 2017.
DOI : 10.1016/j.cell.2017.08.019

I. Hers, E. Vincent, and J. Tavare, Akt signalling in health and disease, Cellular Signalling, vol.23, issue.10, pp.1515-1542, 2011.
DOI : 10.1016/j.cellsig.2011.05.004

R. Hresko and M. M. Mtor, Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes, Journal of Biological Chemistry, vol.19, issue.49, pp.40406-40422, 2005.
DOI : 10.1074/jbc.273.45.29600

D. Sarbassov, D. Guertin, S. Ali, and D. Sabatini, Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex, Science, vol.307, issue.5712, pp.1098-101, 2005.
DOI : 10.1126/science.1106148

J. Garcia-martinez and D. Alessi, mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1), Biochemical Journal, vol.416, issue.3, pp.375-85, 2008.
DOI : 10.1042/BJ20081668
URL : https://hal.archives-ouvertes.fr/hal-00479087

F. Zhang, X. Zhang, M. Li, P. Chen, B. Zhang et al., mTOR Complex Component Rictor Interacts with PKC?? and Regulates Cancer Cell Metastasis, Cancer Research, vol.70, issue.22, pp.9360-70, 2010.
DOI : 10.1158/0008-5472.CAN-10-0207
URL : http://cancerres.aacrjournals.org/content/canres/70/22/9360.full.pdf

D. Sarbassov, S. Ali, D. Kim, D. Guertin, R. Latek et al., Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton, Current Biology, vol.14, issue.14, pp.1296-302, 2004.
DOI : 10.1016/j.cub.2004.06.054

E. Cerami, J. Gao, U. Dogrusoz, B. Gross, S. Sumer et al., The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1., Cancer Discovery, vol.2, issue.5, pp.401-405, 2012.
DOI : 10.1158/2159-8290.CD-12-0095

J. Gao, B. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross et al., Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal, Science Signaling, vol.26, issue.18, p.1, 2013.
DOI : 10.1093/bioinformatics/btq430

N. Sakre, G. Wildey, M. Behtaj, A. Kresak, M. Yang et al., RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR, Oncotarget, vol.8, issue.4, pp.5992-6002, 2017.
DOI : 10.18632/oncotarget.13362

H. Cheng, Y. Zou, J. Ross, K. Wang, X. Liu et al., RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors, Cancer Discovery, vol.5, issue.12, pp.1262-70, 2015.
DOI : 10.1158/2159-8290.CD-14-0971

S. Kim, S. Kim, S. Klempner, J. Yoon, N. Kim et al., ) Amplification Defines a Subset of Advanced Gastric Cancer and is Sensitive to AZD2014-mediated mTORC1/2 Inhibition, Annals of Oncology, vol.28, pp.547-54, 2017.
DOI : 10.1093/annonc/mdw669

Y. Bian, Z. Wang, J. Xu, W. Zhao, H. Cao et al., Elevated Rictor expression is associated with tumor progression and poor prognosis in patients with gastric cancer, Biochemical and Biophysical Research Communications, vol.464, issue.2, pp.534-574, 2015.
DOI : 10.1016/j.bbrc.2015.07.001

W. Jiang, R. Feng, J. Liu, L. Fan, H. Wang et al., RICTOR expression in esophageal squamous cell carcinoma and its clinical significance, Medical Oncology, vol.17, issue.11, p.32, 2017.
DOI : 10.1517/13543784.17.11.1717

F. Laugier, A. Finet-benyair, J. Andre, P. Rachakonda, R. Kumar et al., RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma, Oncotarget, vol.6, issue.29, pp.28120-28151, 2015.
DOI : 10.18632/oncotarget.4866

M. Joly, M. Hicks, D. Jones, B. Sanchez, V. Estrada et al., Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers, Cancer Research, vol.76, issue.16, pp.4752-64, 2016.
DOI : 10.1158/0008-5472.CAN-15-3393

J. Masri, A. Bernath, J. Martin, O. Jo, R. Vartanian et al., mTORC2 Activity Is Elevated in Gliomas and Promotes Growth and Cell Motility via Overexpression of Rictor, Cancer Research, vol.67, issue.24, pp.11712-11732, 2007.
DOI : 10.1158/0008-5472.CAN-07-2223

K. Tanaka, I. Babic, D. Nathanson, D. Akhavan, D. Guo et al., Oncogenic EGFR Signaling Activates an mTORC2-NF-??B Pathway That Promotes Chemotherapy Resistance, Cancer Discovery, vol.1, issue.6, pp.524-562, 2011.
DOI : 10.1158/2159-8290.CD-11-0124
URL : http://cancerdiscovery.aacrjournals.org/content/candisc/1/6/524.full.pdf

M. Kaibori, N. Shikata, T. Sakaguchi, M. Ishizaki, K. Matsui et al., Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma, Digestive Diseases and Sciences, vol.20, issue.4, pp.919-947, 2015.
DOI : 10.1158/1078-0432.CCR-13-0547

K. Schmidt, C. Hellerbrand, P. Ruemmele, C. Michalski, B. Kong et al., Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models, Oncotarget, vol.8, issue.15, pp.24491-505, 2017.
DOI : 10.18632/oncotarget.15524

H. Li, J. Lin, X. Wang, G. Yao, L. Wang et al., Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer, Breast Cancer Research and Treatment, vol.39, issue.2, pp.1057-66, 2012.
DOI : 10.1042/BST0390431

M. Lin, K. Rojas, R. Cerione, and K. Wilson, Identification of mTORC2 as a Necessary Component of HRG/ErbB2-Dependent Cellular Transformation, Molecular Cancer Research, vol.12, issue.6, pp.940-52, 2014.
DOI : 10.1158/1541-7786.MCR-13-0555

D. Driscoll, S. Karim, M. Sano, D. Gay, W. Jacob et al., mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer, Cancer Research, vol.76, issue.23, pp.6911-6934, 2016.
DOI : 10.1158/0008-5472.CAN-16-0810

T. Sticz, A. Molnar, A. Mark, M. Hajdu, N. Nagy et al., mTOR activity and its prognostic significance in human colorectal carcinoma depending on C1 and C2 complex-related protein expression, Journal of Clinical Pathology, vol.36, issue.5, pp.410-416, 2017.
DOI : 10.1136/jclinpath-2016-203913

P. Gulhati, K. Bowen, J. Liu, P. Stevens, P. Rychahou et al., mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways, Cancer Research, vol.71, issue.9, pp.3246-56, 2011.
DOI : 10.1158/0008-5472.CAN-10-4058

C. Oneyama, Y. Kito, R. Asai, J. Ikeda, T. Yoshida et al., MiR-424/503-Mediated Rictor Upregulation Promotes Tumor Progression, PLoS ONE, vol.13, issue.11, p.80300, 2013.
DOI : 10.1371/journal.pone.0080300.s003
URL : https://doi.org/10.1371/journal.pone.0080300

A. Lampada, O. Prey, J. Szabadkai, G. Ryan, K. Hochhauser et al., mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism, Cell Death and Differentiation, vol.1, issue.6, pp.1045-62, 2017.
DOI : 10.1126/science.1246981

M. Verreault, S. Weppler, A. Stegeman, C. Warburton, D. Strutt et al., Combined RNAi-Mediated Suppression of Rictor and EGFR Resulted in Complete Tumor Regression in an Orthotopic Glioblastoma Tumor Model, PLoS ONE, vol.25, issue.3, p.59597, 2013.
DOI : 10.1371/journal.pone.0059597.g008

A. Benavides-serrato, J. Lee, B. Holmes, K. Landon, T. Bashir et al., Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma, PLOS ONE, vol.290, issue.24, p.176599, 2017.
DOI : 10.1371/journal.pone.0176599.s007

Y. Bian, J. Xu, W. Zhao, Z. Zhang, L. Tu et al., Targeting mTORC2 component rictor inhibits cell proliferation and promotes apoptosis in gastric cancer, Am J Transl Res, vol.9, pp.4317-4347, 2017.

B. Guan, K. Wu, J. Zeng, S. Xu, L. Mu et al., Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer, Oncotarget, vol.8, issue.5, pp.8162-72, 2017.
DOI : 10.18632/oncotarget.14131

X. Liang, R. Sun, X. Zhao, Y. Zhang, Q. Gu et al., the AKT-MMP-2/9 pathway, Journal of Cellular and Molecular Medicine, vol.36, issue.12, 2017.
DOI : 10.1007/s13277-015-3187-7

S. Wen, C. Li, Y. Zhang, Y. Bian, L. Ma et al., Rictor is an independent prognostic factor for endometrial carcinoma, Int J Clin Exp Pathol, vol.7, pp.2068-78, 2014.
DOI : 10.1007/s13277-014-1953-6

W. Jia, A. Sanders, G. Jia, X. Liu, R. Lu et al., Expression of the mTOR pathway regulators in human pituitary adenomas indicates the clinical course, Anticancer Res, vol.33, pp.3123-3154, 2013.

A. Uesugi, K. Kozaki, T. Tsuruta, M. Furuta, K. Morita et al., The Tumor Suppressive MicroRNA miR-218 Targets the mTOR Component Rictor and Inhibits AKT Phosphorylation in Oral Cancer, Cancer Research, vol.71, issue.17, pp.5765-78, 2011.
DOI : 10.1158/0008-5472.CAN-11-0368

G. Micevic, V. Muthusamy, W. Damsky, N. Theodosakis, X. Liu et al., DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR, Cell Reports, vol.14, issue.9, pp.2180-92, 2016.
DOI : 10.1016/j.celrep.2016.02.010

C. Chen, S. Jeon, P. Bhaskar, V. Nogueira, D. Sundararajan et al., FoxOs Inhibit mTORC1 and Activate Akt by Inducing the Expression of Sestrin3 and Rictor, Developmental Cell, vol.18, issue.4, pp.592-604, 2010.
DOI : 10.1016/j.devcel.2010.03.008

A. Lin, H. Piao, L. Zhuang, D. Sarbassov-dos, L. Ma et al., FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K???AKT Pathway, Cancer Research, vol.74, issue.6, pp.1682-93, 2014.
DOI : 10.1158/0008-5472.CAN-13-1729

N. Li, W. Xue, H. Yuan, B. Dong, Y. Ding et al., AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis, Journal of Clinical Investigation, vol.127, issue.4, pp.1284-302, 2017.
DOI : 10.1172/JCI91144DS1

A. Daulat, F. Bertucci, S. Audebert, A. Serge, P. Finetti et al., PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2, Developmental Cell, vol.37, issue.4, pp.311-336, 2016.
DOI : 10.1016/j.devcel.2016.04.011
URL : https://hal.archives-ouvertes.fr/hal-01321061

M. Joly, M. Williams, M. Hicks, D. Jones, B. Sanchez et al., Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis, Breast Cancer Research, vol.9, issue.4, p.74, 2017.
DOI : 10.1038/nrc2622

Z. Guo, Y. Zhou, B. Evers, and Q. Wang, Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells, Biochemical and Biophysical Research Communications, vol.418, issue.2, pp.426-458, 2012.
DOI : 10.1016/j.bbrc.2012.01.054

J. Koo, X. Wu, Z. Mao, F. Khuri, and S. Sun, Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation, Journal of Biological Chemistry, vol.290, issue.22, pp.14120-14129, 2015.
DOI : 10.1126/science.1106148
URL : http://www.jbc.org/content/290/22/14120.full.pdf

Y. Yin, H. Hua, M. Li, S. Liu, Q. Kong et al., mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR, Cell Research, vol.16, issue.1, pp.46-65, 2016.
DOI : 10.1038/nm.2091

F. Chiarini, C. Evangelisti, J. Mccubrey, and A. Martelli, Current treatment strategies for inhibiting mTOR in cancer, Trends in Pharmacological Sciences, vol.36, issue.2, pp.124-159, 2015.
DOI : 10.1016/j.tips.2014.11.004

Z. Zou, J. Chen, J. Yang, and X. Bai, Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin, Current Cancer Drug Targets, vol.16, issue.4, pp.288-304, 2016.
DOI : 10.2174/1568009616666151113120830